{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:02:26Z","timestamp":1777482146625,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11606-026-10228-6","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:04:44Z","timestamp":1769529884000},"page":"1515-1522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polypharmacy Among US Older Adults with Limited English Proficiency: 2013\u20132018"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-0217","authenticated-orcid":false,"given":"Yimei","family":"Wan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Jane","family":"Muir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"10228_CR1","unstructured":"US Census Bureau. The Older Population: 2020.  https:\/\/www.census.gov\/library\/publications\/2023\/decennial\/c2020br-07.html.  Accessed 20 Mar 2025."},{"key":"10228_CR2","unstructured":"US Census Bureau. National Population Projections Tables: Main Series. 2023.  https:\/\/www.census.gov\/data\/tables\/2023\/demo\/popproj\/2023-summary-tables.html. Accessed 27 Mar 2025."},{"key":"10228_CR3","doi-asserted-by":"publisher","unstructured":"Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J. 2014;44(4):1055-1068.  https:\/\/doi.org\/10.1183\/09031936.00059814.","DOI":"10.1183\/09031936.00059814"},{"key":"10228_CR4","doi-asserted-by":"crossref","unstructured":"Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096-1099.","DOI":"10.1136\/bmj.315.7115.1096"},{"key":"10228_CR5","doi-asserted-by":"publisher","unstructured":"Young EH, Pan S, Yap AG, Reveles KR, Bhakta K. Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016. PLoS ONE. 2021;16(8):e0255642.  https:\/\/doi.org\/10.1371\/journal.pone.0255642.","DOI":"10.1371\/journal.pone.0255642"},{"key":"10228_CR6","doi-asserted-by":"publisher","unstructured":"Charlesworth CJ, Smit E, Lee DSH, Alramadhan F, Odden MC. Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988\u20132010. J Gerontol A Biol Sci Med Sci. 2015;70(8):989.  https:\/\/doi.org\/10.1093\/gerona\/glv013.","DOI":"10.1093\/gerona\/glv013"},{"key":"10228_CR7","doi-asserted-by":"publisher","unstructured":"Innes GK, Ogden CL, Crentsil V, Concato J, Fakhouri TH. Prescription Medication Use Among Older Adults in the US. JAMA Intern Med. 2024;184(9):1121-1123.  https:\/\/doi.org\/10.1001\/jamainternmed.2024.2781.","DOI":"10.1001\/jamainternmed.2024.2781"},{"key":"10228_CR8","doi-asserted-by":"publisher","unstructured":"Wang X, Liu K, Shirai K, et al. Prevalence and trends of polypharmacy in U.S. adults, 1999\u20132018. Glob Health Res Policy. 2023;8:25.  https:\/\/doi.org\/10.1186\/s41256-023-00311-4.","DOI":"10.1186\/s41256-023-00311-4"},{"key":"10228_CR9","doi-asserted-by":"publisher","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230.  https:\/\/doi.org\/10.1186\/s12877-017-0621-2.","DOI":"10.1186\/s12877-017-0621-2"},{"key":"10228_CR10","doi-asserted-by":"publisher","unstructured":"Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989-995.  https:\/\/doi.org\/10.1016\/j.jclinepi.2012.02.018.","DOI":"10.1016\/j.jclinepi.2012.02.018"},{"key":"10228_CR11","doi-asserted-by":"publisher","unstructured":"Hilmer S, Gnjidic D. The Effects of Polypharmacy in Older Adults. Clin Pharmacol Ther. 2009;85(1):86-88.  https:\/\/doi.org\/10.1038\/clpt.2008.224.","DOI":"10.1038\/clpt.2008.224"},{"key":"10228_CR12","doi-asserted-by":"publisher","unstructured":"Hilmer SN, Gnjidic D, Abernethy DR. Pharmacoepidemiology in the Postmarketing Assessment of the Safety and Efficacy of Drugs in Older Adults. J Gerontol A Biol Sci Med Sci. 2012;67A(2):181-188.  https:\/\/doi.org\/10.1093\/gerona\/glr066.","DOI":"10.1093\/gerona\/glr066"},{"key":"10228_CR13","doi-asserted-by":"publisher","unstructured":"Frazier SC. Health Outcomes and Polypharmacy in Elderly Individuals. J Gerontol Nurs. 2005;31(9):4-9.  https:\/\/doi.org\/10.3928\/0098-9134-20050901-04.","DOI":"10.3928\/0098-9134-20050901-04"},{"key":"10228_CR14","doi-asserted-by":"publisher","unstructured":"Fried TR, O\u2019Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health Outcomes Associated with Polypharmacy in Community-Dwelling Older Adults: A Systematic Review. J Am Geriatr Soc. 2014;62(12):2261.  https:\/\/doi.org\/10.1111\/jgs.13153.","DOI":"10.1111\/jgs.13153"},{"key":"10228_CR15","doi-asserted-by":"publisher","unstructured":"Gnjidic D, Hilmer SN, Blyth FM, et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91(3):521-528.  https:\/\/doi.org\/10.1038\/clpt.2011.258.","DOI":"10.1038\/clpt.2011.258"},{"key":"10228_CR16","doi-asserted-by":"publisher","unstructured":"Blake AJ, Morgan K, Bendall MJ, et al. Falls by elderly people at home: prevalence and associated factors. Age Ageing. 1988;17(6):365-372.  https:\/\/doi.org\/10.1093\/ageing\/17.6.365.","DOI":"10.1093\/ageing\/17.6.365"},{"key":"10228_CR17","doi-asserted-by":"publisher","unstructured":"Ming Y, Zecevic A. Medications & Polypharmacy Influence on Recurrent Fallers in Community: a Systematic Review. Can Geriatr J. 2018;21(1):14-25.  https:\/\/doi.org\/10.5770\/cgj.21.268.","DOI":"10.5770\/cgj.21.268"},{"key":"10228_CR18","doi-asserted-by":"publisher","unstructured":"Zaninotto P, Huang YT, Di Gessa G, Abell J, Lassale C, Steptoe A. Polypharmacy is a risk factor for hospital admission due to a fall: evidence from the English Longitudinal Study of Ageing. BMC Publ Health. 2020;20(1):1804. https:\/\/doi.org\/10.1186\/s12889-020-09920-x","DOI":"10.1186\/s12889-020-09920-x"},{"key":"10228_CR19","doi-asserted-by":"publisher","unstructured":"Jyrkk\u00e4 J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20(5):514-522.  https:\/\/doi.org\/10.1002\/pds.2116.","DOI":"10.1002\/pds.2116"},{"key":"10228_CR20","doi-asserted-by":"publisher","unstructured":"Espino DV, Bazaldua OV, Palmer RF, et al. Suboptimal medication use and mortality in an older adult community-based cohort: results from the Hispanic EPESE Study. J Gerontol A Biol Sci Med Sci. 2006;61(2):170-175. https:\/\/doi.org\/10.1093\/gerona\/61.2.170","DOI":"10.1093\/gerona\/61.2.170"},{"key":"10228_CR21","doi-asserted-by":"publisher","unstructured":"Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc JAPhA. 2017;57(6):729-738.e10.  https:\/\/doi.org\/10.1016\/j.japh.2017.06.002.","DOI":"10.1016\/j.japh.2017.06.002"},{"key":"10228_CR22","doi-asserted-by":"publisher","unstructured":"Kwak MJ, Chang M, Chiadika S, et al. Healthcare Expenditure Associated with Polypharmacy in Older Adults with Cardiovascular Diseases. Am J Cardiol. 2022;169:156-158.  https:\/\/doi.org\/10.1016\/j.amjcard.2022.01.012.","DOI":"10.1016\/j.amjcard.2022.01.012"},{"key":"10228_CR23","unstructured":"U.S. Census Bureau. Language Spoken at Home: American Community Survey, 2023: American Community Survey 1-Year Estimates, Table S1601.  https:\/\/data.census.gov\/table\/ACSST1Y2019.S1601?q=S16&d=ACS%201-Year%20Estimates%20Subject%20Tables. Accessed 16 Dec 2024."},{"key":"10228_CR24","unstructured":"Bureau UC. Detailed Languages Spoken at Home and Ability to Speak English for the Population 5 Years and Over: 2009-2013.  https:\/\/www.census.gov\/data\/tables\/2013\/demo\/2009-2013-lang-tables.html. Accessed 19 Mar 2025."},{"key":"10228_CR25","doi-asserted-by":"publisher","unstructured":"Sentell T, Braun KL. Low health literacy, limited English proficiency, and health status in Asians, Latinos, and other racial\/ethnic groups in California. J Health Commun. 2012;17Suppl 3(Suppl 3):82\u201399. https:\/\/doi.org\/10.1080\/10810730.2012.712621","DOI":"10.1080\/10810730.2012.712621"},{"key":"10228_CR26","doi-asserted-by":"publisher","unstructured":"Himmelstein J, Himmelstein DU, Woolhandler S, et al. Health Care Spending And Use Among Hispanic Adults With And Without Limited English Proficiency, 1999\u20132018. Health Aff (Millwood). 2021;40(7):1126-1134.  https:\/\/doi.org\/10.1377\/hlthaff.2020.02510.","DOI":"10.1377\/hlthaff.2020.02510"},{"key":"10228_CR27","doi-asserted-by":"publisher","unstructured":"Himmelstein J, Cai C, Himmelstein DU, et al. Specialty care utilization among adults with limited english proficiency. J Gen Intern Med. 2022;37(16):4130-4136. https:\/\/doi.org\/10.1007\/s11606-022-07477-6","DOI":"10.1007\/s11606-022-07477-6"},{"key":"10228_CR28","doi-asserted-by":"publisher","unstructured":"Foiles Sifuentes AM, Robledo Cornejo M, Li NC, Castaneda-Avila MA, Tjia J, Lapane KL. The Role of Limited English Proficiency and Access to Health Insurance and Health Care in the Affordable Care Act Era. Health Equity. 2020;4(1):509-517.  https:\/\/doi.org\/10.1089\/heq.2020.0057.","DOI":"10.1089\/heq.2020.0057"},{"key":"10228_CR29","doi-asserted-by":"publisher","unstructured":"Lu T, Myerson R. Disparities in Health Insurance Coverage and Access to Care by English Language Proficiency in the USA, 2006\u20132016. J Gen Intern Med. 2020;35(5):1490-1497.  https:\/\/doi.org\/10.1007\/s11606-019-05609-z.","DOI":"10.1007\/s11606-019-05609-z"},{"key":"10228_CR30","doi-asserted-by":"publisher","unstructured":"Wilson E, Chen AH, Grumbach K, Wang F, Fernandez A. Effects of Limited English Proficiency and Physician Language on Health Care Comprehension. J Gen Intern Med. 2005;20(9):800.  https:\/\/doi.org\/10.1111\/j.1525-1497.2005.0174.x.","DOI":"10.1111\/j.1525-1497.2005.0174.x"},{"key":"10228_CR31","doi-asserted-by":"publisher","unstructured":"McQuaid EL, Landier W. Cultural Issues in Medication Adherence: Disparities and Directions. J Gen Intern Med. 2018;33(2):200-206.  https:\/\/doi.org\/10.1007\/s11606-017-4199-3.","DOI":"10.1007\/s11606-017-4199-3"},{"key":"10228_CR32","doi-asserted-by":"publisher","unstructured":"Al Shamsi H, Almutairi AG, Al Mashrafi S, Al Kalbani T. Implications of Language Barriers for Healthcare: A Systematic Review. Oman Med J. 2020;35(2):e122.  https:\/\/doi.org\/10.5001\/omj.2020.40.","DOI":"10.5001\/omj.2020.40"},{"key":"10228_CR33","doi-asserted-by":"publisher","unstructured":"Twersky SE, Jefferson R, Garcia-Ortiz L, Williams E, Pina C. The Impact of Limited English Proficiency on Healthcare Access and Outcomes in the U.S.: A Scoping Review. Healthcare. 2024;12(3):364.  https:\/\/doi.org\/10.3390\/healthcare12030364.","DOI":"10.3390\/healthcare12030364"},{"key":"10228_CR34","doi-asserted-by":"publisher","unstructured":"Muir KJ, Sliwinski K, Lasater KB. Reducing disparities in emergency department outcomes for individuals with limited English proficiency: The nurse work environment. Nurs Outlook. 2025;73(1).  .https:\/\/doi.org\/10.1016\/j.outlook.2024.102318","DOI":"10.1016\/j.outlook.2024.102318"},{"key":"10228_CR35","doi-asserted-by":"publisher","unstructured":"Sliwinski K, McHugh MD, Squires AP, Jane Muir K, Lasater KB. Nurse Work Environment and Hospital Readmission Disparities Between Patients With and Without Limited English Proficiency. Res Nurs Health. 2025;48(3):398-405.  https:\/\/doi.org\/10.1002\/nur.22462.","DOI":"10.1002\/nur.22462"},{"key":"10228_CR36","doi-asserted-by":"publisher","unstructured":"Jacobs EA, Lauderdale DS, Meltzer D, Shorey JM, Levinson W, Thisted RA. Impact of interpreter services on delivery of health care to limited-English-proficient patients. J Gen Intern Med. 2001;16(7):468-474.  https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016007468.x.","DOI":"10.1046\/j.1525-1497.2001.016007468.x"},{"key":"10228_CR37","doi-asserted-by":"publisher","unstructured":"Kahler L, LeMaster J. Understanding Medication Adherence in Patients with Limited English Proficiency. Kans J Med. 2022;15:31-36.  https:\/\/doi.org\/10.17161\/kjm.vol15.15912.","DOI":"10.17161\/kjm.vol15.15912"},{"key":"10228_CR38","doi-asserted-by":"publisher","unstructured":"Malhotra R, Suppiah S, Tan YW, et al. Validation of pharmaceutical pictograms among older adults with limited English proficiency. Patient Educ Couns. 2022;105(4):909-916.  https:\/\/doi.org\/10.1016\/j.pec.2021.07.015.","DOI":"10.1016\/j.pec.2021.07.015"},{"key":"10228_CR39","doi-asserted-by":"crossref","unstructured":"Lipton HL, Bero LA, Bird JA, McPhee SJ. The Impact of Clinical Pharmacists\u2019 Consultations on Physicians\u2019 Geriatric Drug Prescribing: A Randomized Controlled Trial. Med Care. 1992;30(7):646.","DOI":"10.1097\/00005650-199207000-00006"},{"key":"10228_CR40","doi-asserted-by":"publisher","unstructured":"Schmader KE, Hanlon JT, Pieper CF, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med. 2004;116(6):394-401.  https:\/\/doi.org\/10.1016\/j.amjmed.2003.10.031.","DOI":"10.1016\/j.amjmed.2003.10.031"},{"key":"10228_CR41","doi-asserted-by":"publisher","unstructured":"Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045-1051.  https:\/\/doi.org\/10.1016\/0895-4356(92)90144-c.","DOI":"10.1016\/0895-4356(92)90144-c"},{"key":"10228_CR42","doi-asserted-by":"publisher","unstructured":"Samsa GP, Hanlon JT, Schmader KE, et al. A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol. 1994;47(8):891-896.  https:\/\/doi.org\/10.1016\/0895-4356(94)90192-9.","DOI":"10.1016\/0895-4356(94)90192-9"},{"key":"10228_CR43","doi-asserted-by":"publisher","unstructured":"Schmader K, Hanlon JT, Weinberger M, et al. Appropriateness of medication prescribing in ambulatory elderly patients. J Am Geriatr Soc. 1994;42(12):1241-1247.  https:\/\/doi.org\/10.1111\/j.1532-5415.1994.tb06504.x.","DOI":"10.1111\/j.1532-5415.1994.tb06504.x"},{"key":"10228_CR44","doi-asserted-by":"publisher","unstructured":"Hanlon JT, Artz MB, Pieper CF, et al. Inappropriate medication use among frail elderly inpatients. Ann Pharmacother. 2004;38(1):9-14.  https:\/\/doi.org\/10.1345\/aph.1D313.","DOI":"10.1345\/aph.1D313"},{"key":"10228_CR45","doi-asserted-by":"publisher","unstructured":"Cannon KT, Choi MM, Zuniga MA. Potentially inappropriate medication use in elderly patients receiving home health care: a retrospective data analysis. Am J Geriatr Pharmacother. 2006;4(2):134-143.  https:\/\/doi.org\/10.1016\/j.amjopharm.2006.06.010.","DOI":"10.1016\/j.amjopharm.2006.06.010"},{"key":"10228_CR46","doi-asserted-by":"publisher","unstructured":"Ouellet GM, Ouellet JA, Tinetti ME. Principle of rational prescribing and deprescribing in older adults with multiple chronic conditions. Ther Adv Drug Saf. 2018;9(11):639-652.  https:\/\/doi.org\/10.1177\/2042098618791371.","DOI":"10.1177\/2042098618791371"},{"key":"10228_CR47","unstructured":"Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: Evaluating Risks and Deprescribing. Am Fam Physician. 2019;100(1):32-38."},{"key":"10228_CR48","doi-asserted-by":"publisher","unstructured":"Hung A, Kim YH, Pavon JM. Deprescribing in older adults with polypharmacy. BMJ. 2024;385:e074892.  https:\/\/doi.org\/10.1136\/bmj-2023-074892.","DOI":"10.1136\/bmj-2023-074892"},{"key":"10228_CR49","doi-asserted-by":"publisher","unstructured":"Scott IA, Hilmer SN, Reeve E, et al. Reducing Inappropriate Polypharmacy: The Process of Deprescribing. JAMA Intern Med. 2015;175(5):827-834.  https:\/\/doi.org\/10.1001\/jamainternmed.2015.0324.","DOI":"10.1001\/jamainternmed.2015.0324"},{"key":"10228_CR50","doi-asserted-by":"publisher","unstructured":"Tjia J, Velten SJ, Parsons C, Valluri S, Briesacher BA. Studies to Reduce Unnecessary Medication Use in Frail Older Adults: A Systematic Review. Drugs Aging. 2013;30(5):285-307.  https:\/\/doi.org\/10.1007\/s40266-013-0064-1.","DOI":"10.1007\/s40266-013-0064-1"},{"key":"10228_CR51","doi-asserted-by":"publisher","unstructured":"Krishnaswami A, Steinman MA, Goyal P, et al. Deprescribing in Older Adults With Cardiovascular Disease. J Am Coll Cardiol. 2019;73(20):2584-2595.  https:\/\/doi.org\/10.1016\/j.jacc.2019.03.467.","DOI":"10.1016\/j.jacc.2019.03.467"},{"key":"10228_CR52","doi-asserted-by":"publisher","unstructured":"Cole JA, Gon\u00e7alves-Bradley DC, Alqahtani M, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2023;10(10):CD008165.  https:\/\/doi.org\/10.1002\/14651858.CD008165.pub5.","DOI":"10.1002\/14651858.CD008165.pub5"},{"key":"10228_CR53","doi-asserted-by":"publisher","unstructured":"Gray SL, Hart LA, Perera S, Semla TP, Schmader KE, Hanlon JT. Meta-analysis of interventions to reduce adverse drug reactions in older adults. J Am Geriatr Soc. 2018;66(2):282-288. https:\/\/doi.org\/10.1111\/jgs.15195","DOI":"10.1111\/jgs.15195"},{"key":"10228_CR54","doi-asserted-by":"publisher","unstructured":"Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583-623.  https:\/\/doi.org\/10.1111\/bcp.12975.","DOI":"10.1111\/bcp.12975"},{"key":"10228_CR55","doi-asserted-by":"publisher","unstructured":"Stoehr GP, Ganguli M, Seaberg EC, Echement DA, Belle S. Over-the-counter medication use in an older rural community: the MoVIES Project. J Am Geriatr Soc. 1997;45(2):158-65. https:\/\/doi.org\/10.1111\/j.1532-5415.1997.tb04501.x","DOI":"10.1111\/j.1532-5415.1997.tb04501.x"},{"key":"10228_CR56","doi-asserted-by":"publisher","unstructured":"Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(3):337-344.  https:\/\/doi.org\/10.1001\/jama.287.3.337.","DOI":"10.1001\/jama.287.3.337"},{"key":"10228_CR57","unstructured":"Rights (OCR) O for C. Guidance to Federal Financial Assistance Recipients Regarding Title VI Prohibition Against National Origin Discrimination Affecting Limited English Proficient Persons.  2008.  https:\/\/www.hhs.gov\/civil-rights\/for-individuals\/special-topics\/limited-english-proficiency\/guidance-federal-financial-assistance-recipients-title-vi\/index.html. Accessed 12 Jan 2024."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10228-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10228-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10228-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:14:49Z","timestamp":1777385689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10228-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10228"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10228-6","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Agency for Healthcare Research and Quality (R01HS022882), and from Arnold Ventures, and from The Greenwall Foundation;\u00a0formerly received research support from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST); and in addition, Dr. Ross was an expert witness at the request of Relator's attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc. that was settled September 2022. Dr. Ramachandran currently receives research support from Arnold Ventures and from The Greenwall Foundation; formerly received research support from the Stavros Niarchos Foundation and the United States Food and Drug Administration (FDA); receives personal fees Roosevelt Institute outside the submitted work, formerly from the ReAct-Strategic Policy Program, and serves as a member of the board of directors (unpaid) for the nonprofit organization Doctors for America. Dr. Muir reports support from the National Institute of Nursing Research of the National Institutes of Health under grant number K01NR021419. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. No other disclosures were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}